Government liabilities at Rs 93.89 lakh crore at December-end, up 3.2 per cent over Q2


New Delhi: Total liabilities of the government increased to Rs 93.89 lakh crore at the end of December 2019, up 3.2 per cent as compared to the previous quarter, said finance ministry data on Wednesday. The liabilities, including those under the public account, had stood at Rs 91,01,484 crore at the end of September 2019.

Public debt accounted for 90.4 per cent of total outstanding liabilities at the end of December 2019.

The Public Debt Management Quarterly Report further said the proportion of debt (dated securities) maturing in less than one year was higher at 6.64 per cent at the end of December 2019 as compared to its previous quarter level of 5.41 per cent.


The proportion of debt maturing within 1-5 years was also higher at 25.09 per cent at the end of December 2019, compared with 23.65 per cent at end-September 2019.

Debt maturing in the next five years worked out to 31.7 per cent of total outstanding debt at the end of December 2019 or 6.3 per cent of outstanding stock, on an average, needs to be repaid every year over the next five years.

As per the report, the yields on G-Secs moved in a narrow range during October-November 2019, before hardening in the first fortnight of December 2019.

This reflected the impact of several developments, namely reduction in the repo rate by RBI, contraction in IIP for the month of October and simultaneous purchase and sale of government securities in December 2019, the report said.

Central government-dated securities continued to account for a major share of total trading volumes in the secondary market, with a share of 82 per cent in total outright trading volumes in value terms during the third quarter of the current financial year.

Source link

Articles You May Like

Powell says it’s ‘highly unlikely’ the Fed will raise rates this year, despite stronger economy
Govt approves Rs 726 cr highway projects in Madhya Pradesh
How to book a private flight? Mobile apps do the job
Regeneron to request FDA clearance for antibody drug as preventative treatment
Papua New Guinea (PNG) Covid-19 outbreak, vaccine campaign

Leave a Reply

Your email address will not be published. Required fields are marked *